Cite
HARVARD Citation
Martín, M. et al. (2019). Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor–positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials. European journal of cancer. pp. 91-98. [Online].